

Oryzon Genomics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference and at BioPharm America 2016

BARCELONA, SPAIN and CAMBRIDGE, MA, September 1, 2016 – Oryzon Genomics (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today its CEO, Dr. Carlos Buesa, will present a corporate overview at the 18th Annual Rodman and Renshaw Global investment Conference. The conference will take place on September 11-13, 2016, at the Palace Hotel in New York City. Dr. Buesa is scheduled to present on Tuesday, September 13th at 2:35 pm ET.

Dr. Buesa will also present a corporate overview at the 9th Annual International Partnering Conference BioPharm America-2016. The event will take place on September 13-15 in Boston, at the Marriott Copley Place Hotel. Dr. Buesa is scheduled to present on September 14th in the afternoon CNS track starting at 1.30 pm ET.

The Rodman and Renshaw Annual Global Investment Conference provides an excellent opportunity for increased exposure with industry-focused investors. This year's conference will bring growing companies together with a vast audience of financial and strategic investors. Institutional investors are also invited to request a one-on-one meeting with Oryzon Genomics management during the conference by emailing lk@rodmanevents.com or by contacting Oryzon's investor relations' team.

BioPharm America™ is a international partnering event that draws biotechnology and pharmaceutical executives from around the world to identify and enter strategic relationships. Over 900 delegates are expected at this year's conference representing approximately 500 life sciences companies, with extensive one-on-one partnering meeting opportunities, company presentations, and licensing connections.

About Oryzon

Founded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company has one of the strongest portfolios in the field and a clinical asset already partnered with Roche. Oryzon's LSD1 program is currently covered by 20 patent families and has rendered two compounds in clinical trials. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. The company has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurodegenerative diseases. Oryzon's strategy is to develop first in class compounds against novel epigenetic targets through Phase II clinical trials, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization. The company has offices in Barcelona and Cambridge, Massachusetts. For more information, visit www.oryzon.com.

FORWARD-LOOKING STATEMENTS

This communication contains forward-looking information and statements about Oryzon Genomics, S.A., including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates" and similar expressions. Although Oryzon Genomics, S.A. believes that the expectations reflected in such forward-looking

statements are reasonable, investors and holders of Oryzon Genomics, S.A. shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon Genomics, S.A., that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon Genomics, S.A. to the *Comisión Nacional del Mercado de Valores*, which are accessible to the public. Forward-looking statements are not guarantees of future performance. The auditors of Oryzon Genomics, S.A. have not reviewed them. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon Genomics, S.A. or any of its members, directors, officers, employees or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon Genomics, S.A. on the date hereof. Except as required by applicable law, Oryzon Genomics, S.A. does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

US Contact:**The Trout Group****Maria Lomaka**

+1 646 378 2932

mlomaka@troutgroup.com**Spain:****ATREVIA****Patricia Cobo**

+34 91 564 07 25

pcobo@atrevia.com**The Company:****Ms. Anna K Baran****IR Director**

+44 (0) 752 1083 006

abaran@oryzon.com